Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Chan, A T C ^a,c   Felip, E ^b,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX;

ADJUVANT THERAPY; ARTICLE; BRACHYTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDICATION; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; METASTASIS; NASOPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; INCIDENCE; NASOPHARYNX TUMOR; PATHOLOGY; PRACTICE GUIDELINE; TUMOR RECURRENCE;

FOLLOW-UP STUDIES; HUMANS; INCIDENCE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 45149088256     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn098     Document Type: Article

References (11)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase 2004; No. 5, version 2.0, IARC Press, Lyon.
2. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumors. WHO Classification of Tumors 2005; 9.
3. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-1619.
4. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.
5. Leung SF, Zee B, Ma BB et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements TNM staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-5418.
6. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317.
7. Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56.
8. Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124.
9. Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53: 12-22.
10. Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873-4879.
11. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103: 22-31.